Table 2 Characteristics of patients.
Sample number | Tumor type | Cohort | Sex | Age at blood taking (year) | Hormonal activity | Ki-67 (%) or mitotic index (N/10 HPF) | Weiss score | ENSAT Tumor stage |
|---|---|---|---|---|---|---|---|---|
1 | ACC | Screening | F | 51 | Cortisol | 25% | 9 | 1 |
2 | ACC | Screening | F | 62 | Subclinical testosterone | 5/10 HPF | 7 | 3 |
3 | ACC | Screening | F | 46 | Non-secreting | 10/10 HPF | 6 | 4 |
4 | ACC | Screening | M | 43 | Non-secreting | n.d. | 6 | 4 |
5 | ACC | Screening | F | 57 | Non-secreting | 20–25% | 5 | 4 |
6 | ACC | Screening | F | 36 | Cortisol | n.d. | n.d. | 4 |
7 | ACC | Validation | F | 67 | Cortisol | n.d. | n.d. | 4 |
8 | ACC | Validation | F | 39 | Subclinical cortisol | 10% | 7 | 1 |
9 | ACC | Validation | F | 57 | Non-secreting | n.d. | 5 | 4 |
10 | ACC | Validation | M | 80 | Non-secreting | n.d. | 9 | 3 |
11 | ACC | Validation | F | 56 | Testosterone | n.d. | 6 | 2 |
12 | ACC | Validation | M | 53 | Non-secreting | n.d. | 9 | 3 |
13 | ACC | Validation | F | 31 | Cortisol | n.d. | 6 | 2 |
14 | ACC | Validation | F | 58 | Testosterone | 2/10HPF | 4 | 3 |
15 | ACC | Validation | F | 24 | Androgens | 10% | 5 | 2 |
16 | ACC | Validation | F | 22 | Subclinical cortisol and androgens | 10% | 3 | 1 |
17 | ACC | Validation | M | 62 | Cortisol | 30% | 7 | 2 |
18 | ACC | Validation | M | 48 | Cortisol | 15% | 8 | 3 |
19 | ACC | Validation | F | 38 | Cortisol, androgens | 70% | 8 | 2 |
20 | ACC | Validation | F | 32 | Non-secreting | 5% | 3 | 1 |
21 | ACC | Validation | F | 20 | Non-secreting | 5 | 3 | 4 |
22 | ACC | Validation | M | 51 | Non-secreting | 2% | 4 | |
23 | ACA | Screening | F | 64 | Aldosterone | n.d. | n.d. | |
24 | ACA | Screening | F | 73 | Non-secreting | n.d. | n.d. | |
25 | ACA | Screening | F | 63 | Non-secreting | n.d. | n.d. | |
26 | ACA | Screening | F | 59 | Subclinical cortisol | n.d. | n.d. | |
27 | ACA | Screening | F | 77 | Non-secreting | n.d. | n.d. | |
28 | ACA | Screening | F | 61 | Cortisol | n.d. | n.d. | |
29 | ACA | Validation | F | 38 | Non-secreting | n.d. | n.d. | |
30 | ACA | Validation | F | 74 | Non-secreting | n.d. | n.d. | |
31 | ACA | Validation | F | 52 | Non-secreting | n.d. | n.d. | |
32 | ACA | Validation | M | 29 | Non-secreting | n.d. | n.d. | |
33 | ACA | Validation | M | 71 | Non-secreting | n.d. | n.d. | |
34 | ACA | Validation | F | 81 | Non-secreting | n.d. | n.d. | |
35 | ACA | Validation | M | 63 | Non-secreting | n.d. | n.d. | |
36 | ACA | Validation | M | 50 | Non-secreting | n.d. | n.d. | |
37 | ACA | Validation | F | 50 | Cortisol | n.d. | n.d. | |
38 | ACA | Validation | F | 69 | Cortisol | n.d. | n.d. | |
39 | ACA | Validation | F | 46 | Aldosterone | n.d. | n.d. | |
40 | ACA | Validation | M | 62 | Cortisol | n.d. | n.d. | |
41 | ACA | Validation | F | 33 | Cortisol | n.d. | n.d. | |
42 | ACA | Validation | F | 35 | Non-secreting | n.d. | n.d. | |
43 | ACA | Validation | F | 65 | Non-secreting | n.d. | n.d. | |
44 | ACA | Validation | F | 54 | Non-secreting | n.d. | n.d. | |
45 | ACA | Validation | F | 66 | Non-secreting | n.d. | n.d. | |
46 | ACA | Validation | M | 68 | Non-secreting | n.d. | n.d. |
